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Background: Alcohol consumption is a major cause of liver disease in humans. The use and monitoring of
biomarkers associated with early, pre-clinical stages of alcohol-induced liver disease (pre-ALD) could facilitate
diagnosis and treatment, leading to improved outcomes.
Methods: We investigated the pathological, transcriptomic and protein changes in early stages of pre-ALD in mice
fed the Lieber-Decarli liquid diet with or without alcohol for four months to identify biomarkers for the early stage
of alcohol induced liver injury. Mice were sampled after 1, 2 and 4 months treatment.
Results: Pathological examination revealed a modest increase in fatty liver changes in alcohol-treated mice.
Transcriptomics revealed gene alterations at all time points. Most notably, the Igfbp1 (Insulin-Like Growth Factor
Binding Protein 1) was selected as the best candidate gene for early detection of liver damage since it showed
early and continuously enhanced induction during the treatment course. Consistent with the microarray data, both
Igfbp1mRNA expression in the liver tissue and the IGFBP1 serum protein levels showed progressive and significant
increases over the course of pre-ALD development.
Conclusions: The results suggest that in conjunction with other tests, serum IGFBPI protein could provide an easily
measured biomarker for early detection of alcohol-induced liver injury in humans.
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Alcohol consumption is responsible for about four percent
of all disease world wide and is a major lifestyle-related
cause of death in the United States [1], due in large part to
complications from alcohol-induced liver disease (ALD).
Both intrahepatic and extrahepatic stimuli triggered by al-
cohol abuse can cause ALD. Among the effects of inter-
play of these factors are metabolic dysfunctions such as
fatty liver, obesity and excessive levels of hepatic free fatty
acids, often followed by progressive pathologic changes
such as inflammation, hepatomegaly and ultimately fibro-
sis and cirrhosis.
Diagnosis and stage-assessment of ALD provide guid-
ance for treatment options. Diagnosis is presently based* Correspondence: af294@georgetown.edu
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reproduction in any medium, provided the ormainly on physical examination to determine general
health and assessment of alcohol consumption history
coupled with serum biomarker tests such as carbohydrate-
deficient transferrin (CDT) [2] and various laboratory
tests of liver function like aspartate aminotransferase/
alanine aminotransferase ratio (AST/ALT) [3]. While it
remains questionable whether serum CDT measure-
ment reaches the specificity and sensitivity require-
ments for clinical use in the detection of chronic
alcohol abuse [4], the liver function measurements can
reflect liver damage directly. However there is at present
no easily detectable biomarker to assess early stage
changes prior to the appearance of later stage changes
in liver function. Expensive and invasive techniques
such as computerized tomography (CT) and magnetic
resonance imaging (MRI) are frequently used to confirm
the presence of steatosis and steatohepatitis. Liver biopsy
is sometimes required to confirm correct diagnosis. Thus,his is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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markers of early changes in the development of ALD.
Several have been proposed including serum beta-
hexosaminidase [5,6], increased activity of superoxide
dismutase (SOD) and neuron-specific enolase (NSE) in
blood cells [7], increased levels of lymphocyte cyto-
chrome P450 CYP2E1 [8]. A metabolomics study in
mice revealed two metabolites in urine, N-acetylgluta-
mine and N-acetylglycine, that might be useful markers
for ALD [9]. Indole-3-lactic acid and phenyllactic acid
may also be biomarker candidates for early stages of
ALD [10].
Various animal models have been developed to char-
acterize pathological changes of ALD. In particular, two
protocols have been developed in mice that mimic aspects
of ALD development in humans: the Lieber-DeCarli alco-
hol liquid diet [11,12] and the Tsukamoto-French intra-
gastric alcohol feeding protocol [13,14]. Animals on the
Lieber-DeCarli liquid diet display significant liver le-
sions including steatosis, apoptosis, structural alteration
of mitochondria and endoplasmic reticulum and corre-
sponding changes like those found early in human ALD.
The Tsukamoto-French intragastric protocol produces se-
vere liver damage including cirrhosis after a few months
treatment. Certain genetically engineered mouse strains
have also been used to investigate the development of
ALD [15-17].
Here we investigated transcriptomic and pathological
changes observed during early stage pre-ALD in mice
fed the Lieber-Decarli liquid diet to identify biomarkers
diagnostic for early stage pre-ALD. Transcriptomic ap-
proaches were previously used to profile changes in liver
gene expression in mice and rats [18-21] and primates
exposed to toxicants including ethanol [22,23]. The
present study revealed the following: Chronic alcohol
treatment for periods from one to four months led to a
modest increase in fatty liver seen with standard tech-
niques of histopathology. Transcriptomic analysis of
these same livers revealed a gradual increase over time
in the expression of several genes of which Igfbp1 was
chosen as the best candidate for further analysis because:
1) it showed high and consistent levels of alcohol-related
increase; 2) the expression induction was observed even
at the early time point; 3) IGFBP1 protein is liver-related
and standard commercial immunological tests are avail-
able to detect its serum level in human samples. We
suggest, therefore, that this marker, especially the pro-
tein, could be used as a diagnostic biomarker for early
stage pre-ALD in humans. IGFBP1 is a member of the
insulin-like growth factor binding protein (IGFBP) fam-
ily and encodes a secreted protein with an IGFBP do-
main and a thyroglobulin type-I domain. The protein is
strongly expressed in liver and kidney and circulates in
the plasma.Methods
Animals and treatments
Male mice (129/Sv strain, 6–8 weeks old) were fed ad
libitum a liquid diet containing 4% ethanol (Lieber-DeC-
arli Diet, Dyets, Inc., Bethlehem, PA) as described [24].
Control animals were fed an isocaloric diet supplemented
with maltose dextran (Dyets, Inc.). All mice were precon-
ditioned on the control liquid diet for 7 days prior to
switching half to the alcohol-containing arm. After one,
two, or four months on the alcohol or control diets, six
mice from each arm of the study, i.e. control and alcohol-
fed, were killed in a CO2 chamber. These studies were ap-
proved by the Georgetown University Animal Care and
Use Committee.
Tissue collection and histology
Mice were sacrificed at the specified time points. Blood
was collected by cardiac puncture immediately after the
animals became unconsciousness. Blood samples were
stored at room temperature for about 30 minutes to clot
then centrifuged at 2000× g at 4°C for 10 minutes. Sera
from each tube were collected and stored at −70°. Liver tis-
sues were harvested and prepared for histology [24] by
formalin-fixation and embedding in paraffin, sectioned and
stained with hematoxylin and eosin. Histopathology was
performed by a board-certified pathologist at Georgetown
University Medical Center. Portions of liver tissue were
snap-frozen for subsequent RNA analysis.
RNA extraction
Up to 2 g of frozen liver tissue was homogenized in 5 ml
Trizol reagent (Invitrogen, Carlsbad, CA), 1 ml of chloro-
form was added and the samples were centrifuged at
12,000 g for 15 min. The supernatant was collected and
the samples were purified with the RNeasy Midi kit
(Qiagen, CA). RNA quality was determined with an Agi-
lent 2100 Bioanalyzer (Agilent Technologies, Santa Clara,
CA) and the yield was measured with the Nanodrop 2000
(Thermo Scientific, Waltham, MA).
Microarray analysis
Microarray analysis was carried out by standard proce-
dures as described in the Agilent two-color expression
array manual. Equal amounts of total RNA from each
sample of one treatment group were combined to give
about 100 mg total of which 16 μg was used for probe-
labeling with the SuperScript indirect cDNA labeling
system (Invitrogen) [25]. Probes were hybridized to
mouse whole-genome 4x44K oligo microarrays (Agilent
Technologies) following the manufacturer’s instructions.
These arrays contain more than 41,000 unique mouse
genes and transcripts. Two-color array RNA analysis was
performed for each time point. The labeled alcohol-
exposure and the respective control RNA were hybridized
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(dye-switching) fluorescence replicate. The software,
Feature Extraction version 9.1 (Agilent Technologies)
was used to filter, normalize, and calculate the signal in-
tensities and Cy5/Cy3 ratios. The data discussed in this
study were deposited in NCBI's Gene Expression Omni-
bus and are accessible through GEO Series accession
number GSE44237 (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE44237). These data were entered
into a Rosetta Resolver v3.2 Gene Expression Data Ana-
lysis system (Rosetta Biosoftware, WA) for differential,
hierarchical clustering, and trend-change analysis. The
log(Ratio) was obtained by averaging the log(Ratio) of
the reverse fluorescence pair from which the log(Ratio)
error was calculated. Experiments for the different time
courses were clustered using Genesis (http://genome.
tugraz.at) with agglomerative algorithms to visualize
time course dependent changes.Ingenuity pathway analysis (IPA)
Defined differential genes with changes in levels of more
than 2 fold, either increased or decreased, were selected
from each experiment. These gene-sets and correspond-
ing expression values (ratios) for each time point were
loaded into the IPA (Ingenuity Systems, Redwood City,
CA) to generate a dataset. Biological functions and/or
diseases that were most significantly associated with
each set of data were identified using the Functional
Analysis module. Fischer’s exact test was used to calcu-
late a p-values to evaluate the probability that each bio-
logical function and/or disease assigned to that data set
was not due to chance but resulted, in fact, from the
treatment. Each gene in the dataset was mapped to its
corresponding gene in the Ingenuity Pathways Know-
ledge Base to place it in a network of genes ('network
generation'). These genes were then overlaid onto a glo-
bal molecular network developed from information con-
tained in the Ingenuity Pathways Knowledge Base.
Networks for these focus genes were then algorithmic-
ally generated based on their connectivity.GEDI analysis
Gene Expression Dynamics Inspector (GEDI) [26] was
used for analysis and visualization of patterns in the
time-course microarray data. The genes that changed by
more than two-fold at two or more time points were se-
lected for GEDI analysis. The tiles in a two-dimensional
mosaic generated by GEDI represent individual clusters
in a self-organizing map (SOM), where the color of each
tile is determined by the centroid value of a particular
cluster [26]. The complete GEDI program package and de-
tails of the algorithm can be found at http://apps.childrens
hospital.org/clinical/research/ingber/GEDI/gedihome.htm.Validation of levels of Igfbp1 mRNA
Quantitative RT-PCR (qRT-PCR) assays were performed
with a iCycler instrument (Bio-Rad, Hercules, CA), using
iScript one-step RT-PCR kit probes (Bio-Rad). The
primers and probe mix for the Taqman gene expression
assay for Igfbp1 were from ABI (Foster city, CA). β-actin
was used as the internal control. qRT-PCR reactions
were carried out in a total volume of 20 μl iScript kit in-
structions were followed for the thermocycling steps. A
standard curve using serially diluted samples was made
for each experiment. Data were analyzed with the iCy-
cler software. The RNA levels of the target genes in the
template were calculated from standard curves.
ELISA
ELISA kits for measuring levels of IGFBP1 in serum
were from Insight Genomics (Falls Church, VA). The




Experimental values are presented as mean ± SD. Statis-
tical analysis was performed using GraphPad Prism (San
Diego, CA). The significance was determined using two-
tailed student t-test. p-values of less than 0.05 were con-
sidered significant.
Results
General condition of mice
The daily consumption of the liquid diet and individual
body weights were recorded for each mouse. No signifi-
cant differences were observed between the control and
treated mice, which had also been found by others using
similar experimental protocols [24]. Liver tissues were
subjected to hematoxylin and eosin (H&E) histopath-
ology staining and Oil red O staining. The only alcohol-
induced pathological difference observed in the livers at
the two and four month time points was a slight in-
crease in micro-vesicular fat deposition in the treated
mice (Additional file 1: Figure S1, panels 1C to 1F and
Additional file 2: Figure S2).
Expression profiling
Transcriptomic changes in liver tissue associated with
chronic alcohol consumption were evaluated in samples
harvested after one, two, and four months of alcohol
treatment. RNA samples from liver tissues pooled from
six mice of each exposure group were analyzed. How-
ever, it should be noted that pooling may mask certain
small changes in expression (see Discussion). For the
microarray design, two-color arrays were used in which
the labeled RNAs of controls and alcohol-exposures at
each time point were hybridized on a single array. This
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variation. The reverse-fluorescence technical replication
eliminates dye-bias that can occur in labeling.
The quality of the RNA obtained from each liver was
assessed and only RNA samples with an RIN (RNA
integrity number) of at least 7.0 were pooled for micro-
array analysis. Dual color microarray analysis was per-
formed to reveal changes in gene expression between
the alcohol- and control-diet groups at each time point.
In order to compare time-course effects of chronic
alcohol consumption on the liver transcriptome, the
microarray datasets from three time points wereFigure 1 Two dimensional clustering of differential genes in livers of
dimensional clustering of differential genes in livers of alcohol-treated mice
displayed, one-, two-, four-month. This clustering was derived from the rati
induction and repression of a particular gene respectively. The patterns of
Analysis results for differential genes. The orange line indicates the thresho
pathways were modulated by alcohol treatment.analyzed by two-dimensional clustering (Figure 1A). Ex-
pression of about 100 to 200 genes was increased by at
least 2 fold and a roughly equal number showed a de-
creased expression at the three time points of exposure
(Additional file 3: Table S1). On one hand, common
genes were found among the three time points and, on
the other hand, unique signatures occurred among the
different time points. Eight hundred fifty-one sequences
out of 41,000 unique mouse genes and transcripts had a
change of more than 2 fold at one or more time points.
These genes were selected for further Ingenuity path-
way analysis.alcohol-treated mice compared to liquid-diet control. (A) Two
compared to liquid-diet control. Treatments for three time points are
o (treated/control) data. Red and green represented the levels of
change were similar at two- and four-months. (B) Ingenuity Pathway
ld of p-value of 0.05, i.e. -log10(p-value) of 1.3. Several metabolic
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several essential pathways including metabolism of fatty
acids, linoleic acid and arachidonic acid and metabolism
of xenobiotics by cytochromes P450 (Figure 1B). To
visualize the changes in both induction and repression
of gene expression, the genes that had a change of more
than 2 fold at two or more time points were subjected to
a GEDI analysis. The SOM matrix (Figure 2) shows the
time-dependent effect of chronic alcohol intake on liver
gene expression.
Changes in gene expression
Two-dimensional clustering analysis revealed that the
expression of certain genes was altered, either enhanced
or repressed, at all time points in the alcohol treated ani-
mals. The “Trend” analysis in Rosetta Resolver was used
to identify those signatures that showed progressively in-
creased induction (These genes are listed in Additional
file 4: Table S2).
Particular attention was paid to genes that are primarily
expressed in liver. In particular, genes encoding proteins
that can be readily identified in biofluids like blood, whichFigure 2 Changes in gene expression during the four month
treatment period as visualized with GEDI analysis using self-
organizing maps (SOMs). SOMs were constructed from data for
609 genes. Genes with the most robust induction were deep red
while those most repressed were dark blue. Intermediate levels of
change lie between these saturated colors.would provide diagnostic simplification and were thus ex-
amined in more detail. Igfbp1 is a gene that meets these
criteria; it is expressed in liver, showed early and high levels
of induction and its encoded protein, IGFBP1, can be read-
ily quantified in blood by commercially available immuno-
assays. The microarray data showed that the expression
level of Igfbp1 in liver tissue from mice on the alcohol diet
was increased by 1.9-, 3.9- and 6.8-fold, respectively, after
one-, two-, or four- month’s alcohol treatment.
Validation of microarray findings on Igfbp1
To provide validation of the microarray data, qRT-PCR
was performed on individual liver RNA samples. At two
months and four months of alcohol consumption Igfbp1
gene expression was significantly increased in liver tissue
(Figure 3 upper panel). This result is consistent with theFigure 3 Validation of results for mRNA and serum protein
levels of IGFBP1. (A) qRT-PCR was used to validate hepatic Igfbp1
gene expression. The open bars were the control mice; black bars
were for the alcohol-treated animals. (B) Serum levels of IGFBP1
protein measured by ELISA. Increases in the protein levels generally
mimicked changes seen for microarray and qRT-PCT results. Data
were for samples from individual mice, six animals in each group.
For statistical significance, “n.s.” stands for no significance; “**”
indicates a significant difference with a p-value less than 0.01.
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Since IGFBP1 protein is known to be in blood, protein
levels were measured in mouse sera by ELISA (Figure 3
lower panel). Alcohol treatment for two and four months
significantly increased the levels (p-value of 0.002 and
0.001 respectively). The dot plot of serum IGFBP1 meas-
urement is shown in Additional file 5: Figure S3 to display
the individual variation of the tested samples. The changes
in gene expression and protein level at the one-month
time point were not statistically significant. At the later
two time points, the increases in gene expression were
similar to those seen for protein levels. For reasons not
known, IGFBP1 protein levels in control groups at differ-
ent time points varied to certain extent. At two-month
serum IGFBP1 decreased by around 50% when compared
with that of one-month control while the liver IGFBP1
mRNA expression level did not change significantly. At
four-month both liver expression and serum protein level
of IGFBP1 of control group are significantly lower than
that of one-month control. Nevertheless alcohol feeding
remarkably increased IGFBP1 on both liver mRNA ex-
pression and serum protein level, which are shown in
measurements in Figure 3 and supported by the t-test re-
sults in Additional file 6: Table S3.
Discussion
Transcriptomic analysis was applied to screen for markers
of early-stage pre-ALD in mice treated for up to four
months with 4% alcohol by liquid diet. Igfbp1 was identi-
fied as a particularly useful biomarker gene for alcohol-
induced disease because its expression is liver-related, and
expression increased significantly and progressively over
the course of treatment. Furthermore IGFBP1 protein,
which is readily detectable in mouse or human serum by a
commercially available ELISA assays, also increased sig-
nificantly and thus may be to be a good candidate for clin-
ical use in humans.
Transcriptomics has been used to analyze changes in
gene expression in liver associated with alcohol treat-
ment of several species including mice and rats [18-23].
Although the pathways affected were generally the same
from study to study, differences in feeding systems and
other experimental parameters make it difficult to dir-
ectly compare results. For instance the changes in gene
expression were very different in two rat strains treated
in different ways, i.e., Sprague–Dawley rats employing
voluntary alcohol intake and Wistar rats treated via
intragastric introduction of alcohol [27]. In the present
study, induction of genes involved in the metabolism of
fatty acids, lipids, nucleotides, and glutathione, as well as
metabolism of xenobiotics, were observed, consistent with
previous publications. These results are similar to the
gene-profiling study in the C57Bl/6 mouse model of four
weeks’ intragastric ethanol infusion [18]. We observedchanges of pathways and also genes such as induction of
glutathione S-transferases and cytochromes P450. In the
cytochromes P450 family, the specific members including
Cyp2a4, Cyp2c29, and Cyp2b9 showed induction by alco-
hol in both studies.
In this study transcriptomics profiling was performed
on pooled samples from each group to obtain the differ-
entially expressed genes. Statistical implications of such
sample pooling have been discussed [28-30]. In theory, if
individual variations in levels of gene expression have a
normal distribution then pooling samples could serve to
reduce the variance [28,29]. On the other hand, pooling
may hide values for outliers so as to cause loss of actual
information. In a study of rat liver responses to various
toxic agents, the transcriptomics microarray results were
compared for the pooled data and for individual samples
and about 90 percent of the transcript changes seen in
the pooled samples were also found in the individual
samples [30]. However, 50% more expression changes
were observed in the individual samples than were ob-
served in the pooled samples, although most of these ex-
cess changes were subtle. The objective of this study was
to identify biomarkers that are robustly altered by alco-
hol intake. In addition, subtle gene expression changes
are usually associated with low reproducibility. There-
fore, we applied the sample pooling method with the un-
derstanding that we might miss some genes that were
modestly altered by alcohol, but which allowed us to
narrow down the search for the genes with more robust
changes. To assess the individual variation of the se-
lected biomarker, individual liver RNA and serum sam-
ples were used for gene expression and serum protein
validation assays (Figure 3).
We here showed the association of early pre-ALD con-
ditions with increased Igfbp1 expression and increased
levels of IGFBP1 protein in serum. This protein is strongly
expressed in liver and kidney and circulates in the plasma.
The association of alcohol intake and increased levels of
IGFBP1 was reported in rodents and humans, primarily
after acute exposure [31-34]. Several studies showed an
acute increase in levels of IGFBP1 in normal human sub-
jects and in alcohol abusers within 8 hours of alcohol in-
gestion [32-34]. In a study in humans, IGFBP1 levels were
increased in human serum after a single dose of alcohol
had been administration to nine healthy volunteers [31].
In patients with alcoholic liver cirrhosis and ascites, the
IGF affinity profile of the IGFBP family was found mark-
edly altered [35]. However from these human studies, it
remained unclear whether increased levels of IGFBP1 per-
sisted with chronic alcohol consumption and if it did,
whether levels continue to increase in parallel with the de-
velopment of ALD.
Only two studies were found on regulation and levels
of IGFBP1 with chronic alcohol exposure in animals
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rats were fed on alcohol-agar blocks that contained over
30% alcohol. The doses used far exceeded those possible
in human consumption. In addition, only one time-point
was used in these studies, which made it impossible to
assess the development and progress of chronic alcohol
induced liver pathological changes and to address how
Igfbp1 expression change associated with the progress.
In our study, a four-month liquid diet feeding was carried
out with 4% alcohol and samples collected after one, two
and four months. The concentration of our feeding
scheme was closer to the consumption of chronic alco-
holics in human. The mRNA expression and the serum
protein levels of IGFBP1 increased gradually along the
time course of the alcohol exposure. The finding of lower
serum IGFBP1 levels associated with nonalcoholic fatty
liver disease [38] suggests that increased IGFBP1 expres-
sion may be caused by alcohol consumption.
Conclusion
Hepatic expression of Igfbp1 gene and serum level of
IGFBP1 protein were found progressively increased dur-
ing the four months’ treatment course. Histopathology
showed mild fat deposition in alcohol-fed mice. The re-
sults indicate that in conjunction with other tests, IGFBP1
protein in serum could provide an easily measured bio-
marker for early detection of pre-ALD.
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